Almac Group

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Company Type
Twitter Account
@AlmacGroup
News Page URL
Click here

Sygnature Discovery

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facility in Nottingham, UK, housing nearly 400 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.